OnCo
ideasIdea

A pragmatic trial network for intraoperative margin tools, paid on margin reduction

Tools that show surgeons where the tumour ends during the operation could cut the number of patients who need a second operation, but none has been properly tested at scale. A network would run those trials and pay on results.

A standing network of surgical centres running randomised, pragmatic trials of fluorescence-guided surgery agents, intraoperative specimen imaging, optical and mass-spectrometry margin probes and AI-based margin prediction, with positive-margin and re-operation rates as primary endpoints and payer contracts that reimburse devices on demonstrated margin reduction. Several agents and devices are approved or near approval, but adoption is slow because evidence is single-centre and payers are unconvinced. The network would also standardise pathology margin assessment, which varies enough to confound trials.

Hypothesis
The network completes randomised trials of at least five intraoperative margin technologies within four years, at least two of which reduce positive margins or re-operation by a third in breast, head and neck or prostate surgery and are adopted under outcome-based payment.
Rationale
Re-operation rates after breast-conserving surgery run at a fifth in many systems; positive margins predict recurrence in most solid tumours. Pegulicianine and other agents have shown margin detection in trials, but comparative evidence across technologies and payment models is absent.
What would test it
Launch two randomised trials in breast and head and neck surgery with margin primary endpoints and a pilot outcome-based payment contract with one payer.
Maturity
early clinical
Who has to act
clinic
Cost to try
Medium ($1M to $50M)
Years to first evidence
4
Bottlenecks it attacks

Connected

9top

Pages like this

not linked directly; found by shared links

cancers

3
Head and neck squamous cell carcinomaHR-positive / HER2-negative breast cancerProstate cancer

technologies

2
Fluorescence-guided surgeryOptical & fluorescence imaging

ideas

2
A permanently funded international network for randomised cancer surgery trialsA translation fund for academic surgical devices and radiotherapy technology

bottlenecks

2
Surgery and radiotherapy cure most, get leastThe valley of death between lab and product